<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="ml3c" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">ml3c</book-part-id>
      <title-group>
        <title>Mucolipidosis III Gamma</title>
        <alt-title alt-title-type="alt-title">Synonyms: Mucolipidosis III C, Variant Pseudo Hurler Polydystrophy</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Raas-Rothschild</surname>
            <given-names>Annick</given-names>
          </name>
          <degrees>MD</degrees>
          <email>annick@hadassah.org.il</email>
          <aff>Pediatrician Medical Geneticist, Department of Human Genetics<break/>Hadassah Hebrew University Medical Center<break/>Jerusalem, Israel<break/>Institute of Genetics<break/>Meir Hospital<break/>Kfar Saba, Israel</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Spiegel</surname>
            <given-names>Ronen</given-names>
          </name>
          <degrees>MD</degrees>
          <email>spiegelr@zahav.net.il</email>
          <aff>Pediatrician Medical Geneticist, Pediatric Department A and Genetic Institute<break/>Ha&#x02019;Emek Medical Center<break/>Afula, Israel<break/>Rappaport Faculty of Medicine<break/>Technion &#x02013; Israel Institute of Technology<break/>Haifa, Israel</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2010-01-28" date-type="created">
          <day>28</day>
          <month>1</month>
          <year>2010</year>
        </date>
        <date iso-8601-date="2012-07-05" date-type="updated">
          <day>5</day>
          <month>7</month>
          <year>2012</year>
        </date>
        <date iso-8601-date="2011-09-29" date-type="revised">
          <day>29</day>
          <month>9</month>
          <year>2011</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="ml3a" document-type="chapter">Mucolipidosis III Alpha/Beta</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="ml4" document-type="chapter">Mucolipidosis IV</related-object>
      <abstract id="ml3c.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Mucolipidosis III gamma (ML III gamma) is a slowly progressive disorder characterized by childhood onset of radiographic evidence of mild to moderate dysostosis multiplex; joint stiffness and pain initially in the shoulders, hips, and fingers; and gradual mild coarsening of facial features. Cardiorespiratory complications (restrictive lung disease, thickening and insufficiency of the mitral and aortic valves, left ventricular hypertrophy) can be significant. A few affected individuals have mild cognitive impairment. Because ML III gamma has only recently been distinguished from the more common ML III alpha/beta, previously published descriptions of ML III may have inadvertently included both of these disorders. Thus, much is to yet be learned about the specific manifestations and natural history of ML III gamma.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>In ML III gamma the activity of nearly all lysosomal hydrolases is up to tenfold higher in plasma and other body fluids than in normal controls because of inadequate targeting to lysosomes. ML III gamma is caused by pathogenic variants in <italic toggle="yes">GNPTG,</italic> which encodes the gamma subunit of the enzyme UDP-<italic toggle="yes">N</italic>-acetylglucosamine: lysosomal hydrolase <italic toggle="yes">N</italic>-acetylglucosamine 1-phosphotransferase. (Of note, the alpha and beta subunits of this enzyme are encoded by <italic toggle="yes">GNPTAB,</italic> pathogenic variants in which cause ML III alpha/beta.) Molecular genetic testing of <italic toggle="yes">GNPTG</italic> detects two pathogenic variants in more than 95% of individuals with ML III gamma.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Low-impact physical therapy is usually well tolerated. Carpal tunnel signs may require tendon release. In late childhood or early adolescence relief of hip pain becomes important; in older adolescents and adults bilateral hip replacement has been successful. Later in the disease course management focuses on relief of general bone pain associated with osteoporosis. In severe cases, when significant valvular dysfunction disrupts ventricular function, valve replacement should be seriously considered.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Because of concerns about airway management, surgical intervention should be undertaken only in tertiary care settings with pediatric anesthesiologists and intensivists. Persons with valvular involvement should be given antibiotic prophylaxis before minor and major surgical procedures (including dental procedures) to prevent bacterial endocarditis.</p>
          <p><italic toggle="yes">Surveillance:</italic> Yearly outpatient clinic visits unless cardiac and/or respiratory monitoring need more frequent attention; annual orthopedic assessment; annual ophthalmology evaluation to monitor for corneal opacities and the possibility of adult-onset retinal degeneration; ERG for those with suspected retinal abnormalities; annual monitoring by echocardiogram for progressive valvular insufficiency; DEXA scan every five years to monitor for metabolic bone disease.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Stretching exercises because they are ineffective, painful, and may damage the surrounding joint capsule and adjacent tendons.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>ML III gamma is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if the pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="ml3c.Diagnosis">
        <title>Diagnosis</title>
        <sec id="ml3c.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The following clinical features, similar to those for <related-object link-type="booklink" source-id="gene" document-id="ml3a" document-type="chapter">mucolipidosis III alpha/beta</related-object>, contribute to early diagnosis of mucolipidosis III gamma (ML III gamma) but are not by themselves diagnostic [<xref ref-type="bibr" rid="ml3c.REF.raasrothschild.2004.e52">Raas-Rothschild et al 2004</xref>, <xref ref-type="bibr" rid="ml3c.REF.cathey.2009.38">Cathey et al 2009</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Family history of ML III gamma</p>
            </list-item>
            <list-item>
              <p>Growth rate deceleration</p>
            </list-item>
            <list-item>
              <p>Joint stiffness of the fingers, shoulders, and hips</p>
            </list-item>
            <list-item>
              <p>Gradual mild coarsening of facial features</p>
            </list-item>
            <list-item>
              <p>Genu valgum</p>
            </list-item>
            <list-item>
              <p>No organomegaly</p>
            </list-item>
          </list>
          <p>In early childhood skeletal radiographs reveal mild to moderate dysostosis multiplex:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Pelvis and hips.</bold> Hypoplastic iliac bones with flared iliac wings and shallow acetabula and moderate-to-severe dysplasia of the proximal femoral epiphyses giving rise to coxa valga are the most striking radiologic abnormalities in ML III gamma.</p>
            </list-item>
            <list-item>
              <p><bold>Hands and feet.</bold> Diaphyses of metacarpals and phalanges are mildly shortened; carpal bones may be smaller than normal</p>
            </list-item>
            <list-item>
              <p><bold>Ribs.</bold> Widening especially in lateral and frontal (costochondral junction) parts</p>
            </list-item>
            <list-item>
              <p><bold>Spine.</bold> Mild generalized platyspondyly; anterior inferior hook in lower thoracic and/or higher lumbar vertebrae</p>
            </list-item>
          </list>
          <p>In late childhood or adolescence the changes observed on skeletal radiographs worsen with the development of generalized osteopenia.</p>
        </sec>
        <sec id="ml3c.Testing">
          <title>Testing</title>
          <p><bold>Activity of lysosomal hydrolases.</bold> In ML III gamma the activity of nearly all lysosomal hydrolases is up to tenfold higher in serum and other body fluids than in normal controls because mannose-6-phosphate (M6P), which is essential to proper targeting of lysosomal acid hydrolases to lysosomes, cannot be added adequately to the hydrolases (see <xref ref-type="sec" rid="ml3c.Resources">Molecular Genetic Pathogenesis</xref>).</p>
          <p>The following lysosomal hydrolases are of most interest as their increased activity in serum and other body fluids is relevant in the differential diagnosis of ML III and lysosomal storage disorders:</p>
          <list list-type="bullet">
            <list-item>
              <p>&#x003b2;-D-hexosaminidase (EC 3.2.1.52)</p>
            </list-item>
            <list-item>
              <p>&#x003b2;-D-glucuronidase (EC 3.2.1.31)</p>
            </list-item>
            <list-item>
              <p>&#x003b2;-D-galactosidase (EC 3.2.1.23)</p>
            </list-item>
            <list-item>
              <p>&#x003b1;-D-mannosidase (EC 3.2.1.24)</p>
            </list-item>
          </list>
          <p>Note: (1) Lysosomal hydrolase activity in cultured cells, such as skin fibroblasts, is low compared to control cells and permits confirmation of the diagnosis as well. (2) ML III gamma cannot be diagnosed by assay of acid hydrolases in leukocytes. (In ML II, specific activity of lysosomal enzymes is elevated in plasma, deficient in fibroblasts, and normal in leukocytes.) (3) Biochemical testing (measurement of lysosomal hydrolase activity) does not distinguish ML III alpha/beta from ML III gamma. (4) Biochemical testing cannot be used to identify heterozygotes.</p>
          <p><bold>UDP-N-acetylglucosamine: lysosomal hydrolase N-acetylglucosamine-1-phosphotransferase enzyme</bold> (also known as GlcNAc-phosphotransferase) (EC 2.7.8.17). Demonstration of deficiency of the enzyme GlcNAc-phosphotransferase, encoded by <italic toggle="yes">GNPTAB</italic> (causing <related-object link-type="booklink" source-id="gene" document-id="ml3a" document-type="chapter">ML III alpha/beta</related-object>) and <italic toggle="yes">GNPTG</italic> (causing ML III gamma) confirms the diagnosis of ML III alpha/beta and ML III gamma.</p>
          <sec id="ml3c.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">GNPTG</italic> is the only gene in which mutation is known to cause ML III gamma.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <table-wrap id="ml3c.T.summary_of_molecular_genetic_test" position="anchor" orientation="portrait">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Mucolipidosis III Gamma</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ml3c.T.summary_of_molecular_genetic_test_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_ml3c.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_ml3c.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_ml3c.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ml3c.T.summary_of_molecular_genetic_test_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">GNPTG</italic>
                    </td>
                    <td headers="hd_h_ml3c.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_ml3c.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_ml3c.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;95%&#x000a0;<sup>5</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ml3c.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/ duplication analysis&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_ml3c.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon, intron, or whole-gene deletions</td>
                    <td headers="hd_h_ml3c.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ml3c.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Uniparental disomy (UPD) analysis&#x000a0;<sup>8</sup></td>
                    <td headers="hd_h_ml3c.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">UPD of chromosome 16</td>
                    <td headers="hd_h_ml3c.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown; no such reported cases to date</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="ml3c.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="ml3c" object-id="ml3c.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="ml3c.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="ml3c.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="ml3c.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="ml3c.TF.1.4">
                  <label>4. </label>
                  <p>Examples of pathogenic variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="ml3c.TF.1.5">
                  <label>5. </label>
                  <p>Bidirectional sequencing of the coding region and flanking intronic regions detects two pathogenic variants in more than 95% of individuals.</p>
                </fn>
                <fn id="ml3c.TF.1.6">
                  <label>6. </label>
                  <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="ml3c.TF.1.7">
                  <label>7. </label>
                  <p>The frequency of deletions that would not be detected by sequence analysis is unknown; although a few have been reported [<xref ref-type="bibr" rid="ml3c.REF.persichetti.2009.978">Persichetti et al 2009</xref>].</p>
                </fn>
                <fn id="ml3c.TF.1.8">
                  <label>8. </label>
                  <p>UPD of chromosome 16 is theoretically possible but has never been reported as causative of mucolipidosis III.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p>Carrier status for each parent should be confirmed:</p>
            <list list-type="bullet">
              <list-item>
                <p>If the proband appears to be homozygous for a pathogenic variant by sequence analysis. Confirming the carrier status of the parents helps determine if the proband either (a) is a compound heterozygote for the identified pathogenic variant and a deletion or (b) has uniparental disomy (theoretically possible but not reported to date).</p>
              </list-item>
              <list-item>
                <p>On rare occasion to identify affected parents who were previously undiagnosed compound heterozygotes or homozygotes [Raas-Rothschild, personal communication].</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="ml3c.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband</bold> requires the combination of clinical evaluation and laboratory testing. The following order of evaluation is recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Family history of other affected members and the presence of consanguinity</p>
            </list-item>
            <list-item>
              <p>Identification of the characteristic clinical and radiographic findings</p>
            </list-item>
            <list-item>
              <p>Assay of several acid hydrolases in serum (not leukocytes), such as:</p>
              <list list-type="bullet">
                <list-item>
                  <p>&#x003b2;-D-hexosaminidase (EC 3.2.1.52)</p>
                </list-item>
                <list-item>
                  <p>&#x003b2;-D-glucuronidase (EC 3.2.1.31)</p>
                </list-item>
                <list-item>
                  <p>&#x003b2;-D-galactosidase (EC 3.2.1.23)</p>
                </list-item>
                <list-item>
                  <p>&#x003b1;-D-mannosidase (EC 3.2.1.24)</p>
                </list-item>
                <list-item>
                  <p>Arylsulfatase A (EC 3.1.6.1)</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>If the clinical findings cannot distinguish between ML III alpha beta and ML III gamma, sequence analysis of:</p>
              <list list-type="bullet">
                <list-item>
                  <p><italic toggle="yes">GNPTG</italic> if the phenotype is mild OR</p>
                </list-item>
                <list-item>
                  <p><italic toggle="yes">GNPTAB</italic> if the phenotype is moderate or severe</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Sequence analysis of the coding regions and flanking intronic segments of <italic toggle="yes">GNPTG</italic> and/or sequence analysis of the <italic toggle="yes">GNPTG</italic> cDNA if cells are available (lymphoblasts or fibroblasts). Some laboratories prefer sequence analysis of cDNA because of rapid detection of splicing variants; in some instances, this method may be faster and more cost effective.</p>
            </list-item>
            <list-item>
              <p>Consideration of UPD analysis. UPD of chromosome 16 has never been reported as a cause of ML III gamma. Such testing may be appropriate in rare cases (e.g., when the affected child is an apparent homozygote for a pathogenic variant from one parent, the clinical suspicion is high, the other parent is not a carrier, and paternity is confirmed).</p>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variants in the family.</p>
          <p>Note: (1) If the affected child cannot be tested, sequence analysis of <italic toggle="yes">GNPTG</italic> in both carrier parents can be performed to identify the two pathogenic alleles. (2) Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variants in the family.</p>
        </sec>
      </sec>
      <sec id="ml3c.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="ml3c.Clinical_Description">
          <title>Clinical Description</title>
          <p>Mucolipidosis III is a slowly progressive inborn error of metabolism mainly affecting skeletal, joint, and connective tissues. Clinical onset is in early childhood and the progressive course, including cardiac involvement, results in severe functional impairment and significant morbidity. A few affected individuals may display mild cognitive impairment [<xref ref-type="bibr" rid="ml3c.REF.leroy.2007">Leroy 2007</xref>]; but the majority do not.</p>
          <p>Comprehensive clinical data on ML III alpha/beta have been recently published [<xref ref-type="bibr" rid="ml3c.REF.cathey.2009.38">Cathey et al 2009</xref>], whereas only limited data are available on the natural history of ML III gamma. Thus, this review discusses the natural history of ML III in general (MLIII alpha/beta and MLIII gamma) with emphasis on ML III gamma when specifics are known.</p>
          <p><bold>Growth.</bold> Weight and length at birth are within normal limits. Gradual slowing of growth rate begins in early childhood.</p>
          <p>Worsening hip and knee contractures add to the poor growth rate. While frank dwarfism does not occur, the height of individuals with ML III gamma is often below the tenth centile on standard growth curves.</p>
          <p><bold>Craniofacial.</bold> Dysmorphic facial features are absent or minimal in younger children. Coarsening of facial features is more gradual in ML III gamma than ML III alpha/beta.</p>
          <p><bold>Ophthalmologic.</bold> The corneae are clear by routine clinical inspection, but opacities that do not cause ophthalmologic impairment may be appreciated by slit-lamp examination in some persons [<xref ref-type="bibr" rid="ml3c.REF.traboulsi.1986.592">Traboulsi &#x00026; Maumenee 1986</xref>, <xref ref-type="bibr" rid="ml3c.REF.schrader.2011.12">Schrader et al 2011</xref>]. A recent report described progressive retinitis pigmentosa in four affected consanguineous family members beginning in the third and fourth decades with decreasing night vision and leading to significant peripheral and central vision loss and night blindness [<xref ref-type="bibr" rid="ml3c.REF.schrader.2011.12">Schrader et al 2011</xref>]. Monitoring for this potential complication as affected individuals age may be warranted.</p>
          <p><bold>Respiratory.</bold> Mild hoarseness or metallic voice has been reported.</p>
          <p>Persons with ML III gamma are small and have a small airway, reduced tracheal suppleness from stiff connective tissue, and progressive narrowing of the airway from mucosal thickening. The use of a smaller endotracheal tube than for age- and size-matched controls may be necessary.</p>
          <p>Abnormalities of the spine and ribs may limit lung capacity.</p>
          <p><bold>Cardiovascular.</bold> Individuals with ML III are at risk for cardiac involvement. Gradual thickening and subsequent insufficiency of the mitral valve and the aortic valve are common from late childhood onward [<xref ref-type="bibr" rid="ml3c.REF.steet.2005.369">Steet et al 2005</xref>]. Valve replacement may be required; therefore, careful follow-up is needed.</p>
          <p>Rapid progression of cardiac disease is rarely observed in ML III.</p>
          <p><bold>Gastrointestinal.</bold> Hepatomegaly and splenomegaly are absent.</p>
          <p><bold>Skeletal/soft connective tissue.</bold> Stiffness of finger joints, a cardinal feature, is usually the initial manifestation of the disorder. Limited range of motion of the shoulders is common early in the disease course. Genu valgum deformity occurs in all affected individuals early in the disease.</p>
          <p>Hip involvement usually develops during the end of adolescence in ML III gamma (and earlier in ML III alpha/beta). Hip involvement progresses over years, finally resulting in destruction of the proximal femoral epiphyses. Limited hip mobility and lower limb pain can be significant.</p>
          <p>Dupuytren-type palmar contractures may appear from late childhood onward. Moderate to severe claw-like flexion deformity of the fingers worsens with time.</p>
          <p>Carpal tunnel syndrome and tarsal tunnel syndrome have been reported [<xref ref-type="bibr" rid="ml3c.REF.umehara.1997.167">Umehara et al 1997</xref>, <xref ref-type="bibr" rid="ml3c.REF.tylkiszyma_ska.2002.214">Tylki-Szyma&#x00144;ska et al 2002</xref>, <xref ref-type="bibr" rid="ml3c.REF.raasrothschild.2004.e52">Raas-Rothschild et al 2004</xref>, <xref ref-type="bibr" rid="ml3c.REF.smuts.2009.77">Smuts et al 2009</xref>].</p>
          <p>Odontoid dysplasia and atlanto-axial dislocation were reported <xref ref-type="bibr" rid="ml3c.REF.umehara.1997.167">Umehara et al [1997]</xref> in one older individual.</p>
          <p><bold>Neuromotor development and intellect.</bold> Neuromotor development may be delayed mainly in reaching motor milestones. Nevertheless, other aspects of development including language and learning skills fit the expected age. Affected children may require school assistance but mostly because of physical limitations. In most affected individuals cognitive function is within the normal range for age.</p>
          <p><bold>Other.</bold> The skin may become thickened with time.</p>
          <p>Temporomandibular joint dislocation has been reported in one person, leading to difficulties in speech and feeding [<xref ref-type="bibr" rid="ml3c.REF.zolkipli.2005.772">Zolkipli et al 2005</xref>]. Less severe temporomandibular involvement accompanied by feeding inconvenience was also diagnosed in two individuals [Spiegel, unpublished data].</p>
        </sec>
        <sec id="ml3c.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>To date no correlation between severity of disease and type of pathogenic variant has been reported.</p>
        </sec>
        <sec id="ml3c.Nomenclature">
          <title>Nomenclature</title>
          <p><bold>UDP-<italic toggle="yes">N</italic>-acetylglucosamine: lysosomal hydrolase <italic toggle="yes">N</italic>-acetylglucosamine 1-phosphotransferasedeficiency disorders</bold>. This enzyme is the product of two genes: <italic toggle="yes">GNPTAB,</italic> encoding the alpha and beta subunits and <italic toggle="yes">GNPTG,</italic> encoding the gamma subunit [<xref ref-type="bibr" rid="ml3c.REF.bao.1996.31437">Bao et al 1996</xref>]. Pathogenic variants in:</p>
          <list list-type="bullet">
            <list-item>
              <p><italic toggle="yes">GNPTAB</italic> cause the allelic disorders ML III alpha/beta and ML II;</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">GNPTG</italic> cause ML III gamma [<xref ref-type="bibr" rid="ml3c.REF.cathey.2008.512">Cathey et al 2008</xref>].</p>
            </list-item>
          </list>
          <p>The trivial name of this enzyme is UPDGlcNAc 1-P-transferase; thus, the three ML phenotypes can be considered &#x0201c;UPDGlcNAc 1-P-transferase deficiency disorders&#x0201d; [<xref ref-type="bibr" rid="ml3c.REF.leroy.2007">Leroy 2007</xref>].</p>
          <p><bold>Pseudo-Hurler-polydystrophy</bold> was the term used from 1966 by Maroteaux and Lamy when they first delineated ML III. They used this term because of the resemblance of ML III to Hurler disease, or mucopolysaccharidosis I (MPS I) [<xref ref-type="bibr" rid="ml3c.REF.kornfeld.2014">Kornfeld &#x00026; Sly 2014</xref>].</p>
          <p><bold>Mucolipidosis (ML).</bold> The term mucolipidosis was introduced in 1970 by <xref ref-type="bibr" rid="ml3c.REF.spranger.1970.113">Spranger &#x00026; Wiedemann [1970]</xref>, who provided the first clinical classification of the group of metabolic disorders clinically intermediate between the lipidoses and the mucopolysaccharidoses (storage disorders of glycosaminoglycans).</p>
        </sec>
        <sec id="ml3c.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of ML III gamma is as yet unknown; the disorder is considered very rare.</p>
          <p>Most individuals with ML III gamma known to the authors originated from the Mediterranean region [<xref ref-type="bibr" rid="ml3c.REF.raasrothschild.2004.e52">Raas-Rothschild et al 2004</xref>, <xref ref-type="bibr" rid="ml3c.REF.encarna__o.2009.76">Encarna&#x000e7;&#x000e3;o et al 2009</xref>, <xref ref-type="bibr" rid="ml3c.REF.persichetti.2009.978">Persichetti et al 2009</xref>]. However, more recent reports described patients from other geographic regions [<xref ref-type="bibr" rid="ml3c.REF.pohl.2010.124">Pohl et al 2010</xref>, <xref ref-type="bibr" rid="ml3c.REF.gao.2011.107">Gao et al 2011</xref>, <xref ref-type="bibr" rid="ml3c.REF.schrader.2011.12">Schrader et al 2011</xref>], suggesting that the disorder is pan ethnic.</p>
        </sec>
      </sec>
      <sec id="ml3c.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>Recently Kang et al suggested a possible role of the lysosomal M6P formation pathway in the pathogenesis of stuttering [<xref ref-type="bibr" rid="ml3c.REF.kang.2010.677">Kang et al 2010</xref>]. It is unclear whether unaffected carriers of ML II and ML III are at increased risk of developing stuttering.</p>
      </sec>
      <sec id="ml3c.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Mucolipidosis II (ML II) alpha/beta, ML III alpha/beta, and ML III gamma are all UPDGlcNAc 1-P-transferase deficiency disorders (see <xref ref-type="sec" rid="ml3c.Nomenclature">Nomenclature</xref>). Whereas the clinical phenotypes of ML III alpha/beta and ML III gamma can be difficult to distinguish, the severe ML II (I-cell disease) phenotype is easily differentiated.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="ml2" document-type="chapter"><bold>ML II alpha/beta</bold></related-object><bold>.</bold> In ML II, clinical onset is at birth with findings that can include thoracic deformity, kyphosis, clubfeet, deformed long bones, and/or dislocation of the hip(s). The skin is thickened, facial features are coarse, and gingivae are hypertrophic. All children seem to have cardiac involvement, most commonly thickening and insufficiency of the mitral valve and, less frequently, the aortic valve. Progressive mucosal thickening narrows the airways and gradual stiffening of the thoracic cage contributes to respiratory insufficiency, the most common cause of death (usually in early childhood).</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="ml3a" document-type="chapter"><bold>ML III alpha/beta</bold></related-object><bold>.</bold> No specific ethnic predilection has been reported in ML III alpha/beta [<xref ref-type="bibr" rid="ml3c.REF.bargal.2006.359">Bargal et al 2006</xref>, <xref ref-type="bibr" rid="ml3c.REF.cathey.2009.38">Cathey et al 2009</xref>, <xref ref-type="bibr" rid="ml3c.REF.otomo.2009.145">Otomo et al 2009</xref>, <xref ref-type="bibr" rid="ml3c.REF.tappino.2009.e956">Tappino et al 2009</xref>]. If the clinical diagnosis of ML III is strongly suspected and biochemical analysis shows elevated serum concentration of acid hydrolases, <italic toggle="yes">GNPTAB</italic> molecular genetic testing should be performed to confirm the diagnosis of ML III alpha/beta.</p>
        <p><bold>Rheumatologic disorders</bold> are often suspected in individuals with ML III gamma because of slowly decreasing range of motion in large and small joints and increasing pain in the hips [<xref ref-type="bibr" rid="ml3c.REF.brik.1993.133">Brik et al 1993</xref>].</p>
        <p><bold>Rheumatoid arthritis</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/180300">180300</ext-link>) presents with clinical and laboratory signs of inflammation. The activities of the several lysosomal enzymes in serum are normal. Dysostosis multiplex is absent. Family history is not compatible with autosomal recessive inheritance.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="ppr-dysp" document-type="chapter"><bold>Progressive pseudorheumatoid dysplasia</bold></related-object>
<bold>(PPD)</bold> is caused by pathogenic variants in <italic toggle="yes">WISP3</italic>, the gene encoding the WNT1-inducible signaling pathways protein 3. Initially ML III gamma may be confused with PPD because of the joint stiffness, but dysostosis multiplex is not present in PPD and disease course is less progressive.</p>
        <p><bold>Lysosomal storage diseases.</bold> Clinical findings in ML III gamma overlap those observed in nearly all-late onset and/or mild forms of the following <bold>mucopolysaccharidoses</bold> (MPS):</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="mps1" document-type="chapter">MPS I</related-object> (formerly called Hurler-Scheie syndrome or Scheie syndrome)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="hunter" document-type="chapter">MPS II</related-object> (Hunter syndrome)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="gm1-ganglio" document-type="chapter">MPS IV B</related-object> (Morquio disease type B)</p>
          </list-item>
          <list-item>
            <p>MPS VI B (Maroteaux-Lamy disease type B) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/253200">253200</ext-link>)</p>
          </list-item>
          <list-item>
            <p>MPS VII B (Sly disease type B) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/253220">253220</ext-link>)</p>
          </list-item>
        </list>
        <p>Specific biochemical and molecular genetic testing distinguishes between the mucopolysaccharidoses.</p>
      </sec>
      <sec id="ml3c.Management">
        <title>Management</title>
        <sec id="ml3c.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with ML III gamma, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Basic assessment</p>
              <list list-type="bullet">
                <list-item>
                  <p>Growth parameters</p>
                </list-item>
                <list-item>
                  <p>Pain assessment</p>
                </list-item>
                <list-item>
                  <p>Orthopedic and functional assessments</p>
                </list-item>
                <list-item>
                  <p>Psycho-developmental evaluation to follow the individual&#x02019;s developmental progress and program appropriate management</p>
                </list-item>
                <list-item>
                  <p>Skeletal survey</p>
                </list-item>
                <list-item>
                  <p>Metabolic bone disease assessment including evaluation of bone densitometry by DEXA studies and evaluation of biomarkers reflecting bone metabolism [<xref ref-type="bibr" rid="ml3c.REF.robinson.2002.681">Robinson et al 2002</xref>]</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Cardiac</p>
              <list list-type="bullet">
                <list-item>
                  <p>Clinical examination</p>
                </list-item>
                <list-item>
                  <p>ECG</p>
                </list-item>
                <list-item>
                  <p>Echocardiography</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Ophthalmologic evaluation including slit lamp examination, fundoscopy, and visual acuity</p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation for genetic counseling and reproductive decision making</p>
            </list-item>
          </list>
        </sec>
        <sec id="ml3c.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Supportive and symptomatic management is indicated. Psychosocial support of patients and families is recommended.</p>
          <p>No known measures are effective in treating the progressive limitation of motion in large and small joints. Physiotherapy intervention programs need to be adapted to the affected individual&#x02019;s needs.</p>
          <p>Short sessions of aqua therapy that are &#x0201c;low impact&#x0201d; in regard to joint and tendon strain are usually well tolerated.</p>
          <p>Later in the disease course bone pain of variable intensity may become a frequent complaint. Management of pain in the hips is required. In older adolescents and adults with milder ML III gamma, bilateral hip replacement has been successful.</p>
          <p>Casts (especially of the hands) during the night hours are usually well tolerated and seem to improve daily functions.</p>
          <p>Carpal tunnel signs and rarely tarsal tunnel symptoms may require surgical tendon release procedures for temporary relief [<xref ref-type="bibr" rid="ml3c.REF.smuts.2009.77">Smuts et al 2009</xref>].</p>
          <p>In severe cases, when significant valvular dysfunction disrupts ventricular function, valve replacement should be seriously considered.</p>
        </sec>
        <sec id="ml3c.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p><bold>Anesthesia.</bold> As with all storage diseases, anesthesia in ML III gamma must be well planned. Because of concerns about airway management, surgical intervention should be undertaken only in tertiary care settings with pediatric anesthesiologists and intensive care physicians.</p>
          <p>The anesthetic team should be aware of the following issues:</p>
          <list list-type="bullet">
            <list-item>
              <p>Persons with ML III gamma are small and have a small airway, reduced tracheal suppleness from stiff connective tissue, and progressive narrowing of the airway from mucosal thickening. The use of a smaller endotracheal tube than for age- and size-matched controls is necessary.</p>
            </list-item>
            <list-item>
              <p>Fiberoptic intubation must be available.</p>
            </list-item>
            <list-item>
              <p>Persons with ML III gamma have short necks and atlanto-axial instability has been reported [<xref ref-type="bibr" rid="ml3c.REF.umehara.1997.167">Umehara et al 1997</xref>].</p>
            </list-item>
            <list-item>
              <p>Jaw and neck movement can be limited</p>
            </list-item>
            <list-item>
              <p>Abnormalities of the spine and ribs can limit the individual&#x02019;s capacity to breathe and fully expand the lungs.</p>
            </list-item>
          </list>
          <p><bold>Antibiotic prophylaxis.</bold> Persons with valvular involvement should be given antibiotic prophylaxis before minor and major surgical procedures (including dental procedures) to prevent bacterial endocarditis.</p>
        </sec>
        <sec id="ml3c.Surveillance">
          <title>Surveillance</title>
          <p>Young children with ML III gamma and their families usually benefit from out-patient clinic visits once a year, unless cardiac and/or respiratory monitoring need more frequent attention. Orthopedic assessment should be done at least once a year, with more frequent follow-up visits if any deterioration is observed. Annual ophthalmologic assessment should address possible ophthalmologic changes. If necessary, an ERG should be considered to better evaluate for retinal impairment.</p>
          <p>During yearly visits, attention should be paid to pain relief, daily functional abilities, and psychological interventions.</p>
          <p>Although cardiac manifestations are usually asymptomatic, monitoring for progressive valvular insufficiency using echocardiography should occur at least once a year.</p>
          <p>Surveillance for metabolic bone disease includes DEXA scan in five-year intervals.</p>
        </sec>
        <sec id="ml3c.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Vigorous stretching exercises are not recommended because they are ineffective, painful, and may damage the surrounding joint capsule and adjacent tendons.</p>
        </sec>
        <sec id="ml3c.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>If both pathogenic alleles have been identified in the family, testing of at-risk sibs can be pursued. Note, however, that early diagnosis of affected individuals does not delay or halt disease progression [Author, personal observation].</p>
          <p>See <xref ref-type="sec" rid="ml3c.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="ml3c.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Several individuals with ML III alpha/beta have been treated with monthly intra-venous administration of pamidronate, a bisphosphonate. At present information is insufficient about when in the ML III alpha/beta disease course or at what age such treatment should be initiated [<xref ref-type="bibr" rid="ml3c.REF.robinson.2002.681">Robinson et al 2002</xref>; Sillence, personal communication]. In a consensus meeting on the use of bisphosphonate therapy in oligosaccharidoses doubts were raised regarding its usefulness in ML III gamma [<xref ref-type="bibr" rid="ml3c.REF13">MPS Society 2008</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="ml3c.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="ml3c.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Mucolipidosis III gamma is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="ml3c.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one mutant allele).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with ML III gamma are obligate heterozygotes (carriers) for a pathogenic variant.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="ml3c.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified.</p>
        </sec>
        <sec id="ml3c.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>At-risk family members should be informed of their risks of being either affected or carriers. They should be informed of the option of molecular testing when the pathogenic variants in the family are known. This may allow for prenatal diagnosis or preimplantation genetic diagnosis for at-risk pregnancies (see <xref ref-type="sec" rid="ml3c.Prenatal_Testing">Prenatal Testing</xref>).</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="ml3c.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the pathogenic variants have been identified in the family, prenatal diagnosis for pregnancies at increased risk is possible by analysis of DNA extracted from fetal cells obtained by amniocentesis (usually performed at ~15-18 weeks&#x02019; gestation) [<xref ref-type="bibr" rid="ml3c.REF.falikzaccai.2003.211">Falik-Zaccai et al 2003</xref>] or chorionic villus sampling (usually performed at ~10-12 weeks&#x02019; gestation).</p>
          <p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the pathogenic variants have been identified.</p>
        </sec>
      </sec>
      <sec id="ml3c.Resources">
        <title>Resources</title>
      </sec>
      <sec id="ml3c.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="ml3c.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Newly synthesized lysosomal hydrolases have mannose 6-phosphate (M6P) residues that function as recognition markers for specific receptors required for lysosomal targeting. The M6P marker is generated in the Golgi apparatus by the sequential action of two enzymes.</p>
          <p>In the first step N-acetylglucosamine-1-phosphotransferase (GlcNAc-phosphotransferase) transfers GlcNac-1-phosphate to the C6 position mannose residues of acid hydrolases.</p>
          <p>In the second step, N-acetylglucosamine-1-phosphodiester &#x003b1;-N-acetylglucosminidase (uncovering enzyme) removes N-acetylglucosamine residues thus exposing the M6P residues in order to correctly bind to their lysosomal membrane receptor.</p>
          <p>GlcNAc-phosphotransferase is made up of three different subunits: alpha, beta, and gamma in a hexameric &#x003b1;2&#x003b2;2&#x003b3;2 subunit complex [<xref ref-type="bibr" rid="ml3c.REF.bao.1996.31437">Bao et al 1996</xref>]. The three subunits are the product of two genes: <italic toggle="yes">GNPTAB</italic> and <italic toggle="yes">GNPTG</italic>.</p>
          <p><italic toggle="yes">GNPTAB</italic>, the gene encoding the alpha and beta subunits, maps to chromosome 12q23 [<xref ref-type="bibr" rid="ml3c.REF.tiede.2005.1109">Tiede et al 2005</xref>, <xref ref-type="bibr" rid="ml3c.REF.kudo.2006.451">Kudo et al 2006</xref>]. Pathogenic variants in this gene result in <related-object link-type="booklink" source-id="gene" document-id="ml3a" document-type="chapter">mucolipidosis type III alpha/beta</related-object> [<xref ref-type="bibr" rid="ml3c.REF.bargal.2006.359">Bargal et al 2006</xref>] and <related-object link-type="booklink" source-id="gene" document-id="ml2" document-type="chapter">ML II</related-object>.</p>
          <p><italic toggle="yes">GNPTG</italic>, the gene encoding the gamma subunit of GlcNAc-phospotransferse located on chromosome 16p13.3 was identified in 2000 [<xref ref-type="bibr" rid="ml3c.REF.raasrothschild.2000.673">Raas-Rothschild et al 2000</xref>]. Pathogenic variants in this gene result in mucolipidosis type III gamma [<xref ref-type="bibr" rid="ml3c.REF.raasrothschild.2004.e52">Raas-Rothschild et al 2004</xref>]. The exact role of the &#x003b3; subunit in the function of GlcNAc-phosphotransferase is not yet understood. Recent studies have proposed that it is important in the proper maintenance of &#x003b1; and &#x003b2; subunits in the GlcNAc-phosphotransferase complex [<xref ref-type="bibr" rid="ml3c.REF.pohl.2009.221">Pohl et al 2009</xref>].</p>
          <p><bold>Benign allelic variants.</bold>
<italic toggle="yes">GNPTG</italic> contains 11 exons that span 11.13 kb of genomic DNA. It encodes a 305-amino acid protein. After cleavage of the 24-amino acid signal peptide, the mature protein (&#x003b3; subunit) forms disulfide-linked homodimers that become glycosylated at Asn88 and Asn115 [<xref ref-type="bibr" rid="ml3c.REF.raasrothschild.2000.673">Raas-Rothschild et al 2000</xref>, <xref ref-type="bibr" rid="ml3c.REF.tiede.2004.535">Tiede et al 2004</xref>].</p>
          <p><bold>Pathogenic allelic variants.</bold> More than 16 pathogenic variants have been reported (<xref ref-type="table" rid="ml3c.T.selected_gnptg_pathogenic_allelic">Table 2</xref>). They include missense, nonsense, splice site and frameshift variants as well as small intragenic deletions and insertions. In individuals with ML III gamma, homozygous or compound heterozygous variants are detected. To date no correlation between severity of the disease and type of variant has been reported. The list of pathogenic variants and their resultant protein changes are described in <xref ref-type="table" rid="ml3c.T.selected_gnptg_pathogenic_allelic">Table 2</xref>.</p>
          <table-wrap id="ml3c.T.selected_gnptg_pathogenic_allelic" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>Selected <italic toggle="yes">GNPTG</italic> Pathogenic Allelic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                  <th id="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference</th>
                  <th id="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.318-1G&#x0003e;C<break/>(IVS5-1G&#x0003e;C)</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">(Exon 6 skipping)</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.raasrothschild.2004.e52">Raas-Rothschild et al [2004]</xref>
                  </td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_4" rowspan="16" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nucleotide/42476109">NM_032520.3</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/14249738">NP_115909.1</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.196C&#x0003e;T</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg66Ter</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.raasrothschild.2004.e52">Raas-Rothschild et al [2004]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.316G&#x0003e;A</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly106Ser</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.raasrothschild.2004.e52">Raas-Rothschild et al [2004]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.333G&#x0003e;A</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Trp111Ter</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.persichetti.2009.978">Persichetti et al [2009]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.347_349delACA</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asn116del</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.tiede.2004.535">Tiede et al [2004]</xref>
                    <break/>
                    <xref ref-type="bibr" rid="ml3c.REF.persichetti.2009.978">Persichetti et al [2009]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.379_391del13</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asp127ProfsTer31</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.raasrothschild.2004.e52">Raas-Rothschild et al [2004]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.523dupC<break/>(522insC)</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu175ProfsTer24</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.raasrothschild.2000.673">Raas-Rothschild et al [2000]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.608_609insC<break/>(608insC)</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln203HisfsTer4</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.raasrothschild.2004.e52">Raas-Rothschild et al [2004]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.609+28_610-16del33</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.persichetti.2009.978">Persichetti et al [2009]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.610-1C&#x0003e;T<break/>(IVS8-1G&#x0003e;T)</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.encarna__o.2009.76">Encarna&#x000e7;&#x000e3;o et al [2009]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.610-2A&#x0003e;G</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.persichetti.2009.978">Persichetti et al [2009]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.611delG</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly204AlafsTer6</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.persichetti.2009.978">Persichetti et al [2009]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">c.619_620insT</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">p.Lys207IlefsTer8</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.pohl.2009.221">Pohl et al [2009]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.639delT</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Phe213LeufsTer7</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.encarna__o.2009.76">Encarna&#x000e7;&#x000e3;o et al [2009]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.640_667del28</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu214LysfsTer37</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.persichetti.2009.978">Persichetti et al [2009]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.857C&#x0003e;T</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr286Met</td>
                  <td headers="hd_h_ml3c.T.selected_gnptg_pathogenic_allelic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="ml3c.REF.persichetti.2009.978">Persichetti et al [2009]</xref>
                  </td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="ml3c.TF.2.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> The exact role of the &#x003b3; subunit in the function of GlcNAc-phosphotransferase is not entirely understood. Recent studies have proposed that it is important in the proper maintenance of &#x003b1; and &#x003b2; subunits in the GlcNAc-phosphotransferase complex [<xref ref-type="bibr" rid="ml3c.REF.pohl.2009.221">Pohl et al 2009</xref>].</p>
          <p><bold>Abnormal gene product.</bold> Unknown</p>
        </sec>
      </sec>
      <sec id="ml3c.References">
        <title>References</title>
        <sec id="ml3c.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="ml3c.Literature_Cited.reflist0">
            <ref id="ml3c.REF.bao.1996.31437">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bao</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Booth</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elmendorf</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canfield</surname>
                    <given-names>WM</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Bovine UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase. I. Purification and subunit structure.</article-title>
                <source>J Biol Chem</source>
                <volume>271</volume>
                <fpage>31437</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">8940155</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.bargal.2006.359">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bargal</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeigler</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abu-Libdeh</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zuri</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Neriah</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stewart</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elcioglu</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hindi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Merrer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bach</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raas-Rothschild</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>When Mucolipidosis III meets Mucolipidosis II: GNPTA gene mutations in 24 patients</article-title>
                <source>Mol Genet Metab</source>
                <volume>88</volume>
                <fpage>359</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">16630736</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.brik.1993.133">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brik</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aizin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldscher</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ziegler</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bialik</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berant</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>Mucolipidosis III presenting as a rheumatological disorder.</article-title>
                <source>J Rheumatol</source>
                <volume>20</volume>
                <fpage>133</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">8441145</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.cathey.2008.512">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cathey</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kudo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiede</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raas-Rothschild</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braulke</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canfield</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neufeld</surname>
                    <given-names>EF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKusick</surname>
                    <given-names>VA</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Molecular order in mucolipidosis II and III nomenclature.</article-title>
                <source>Am J Med Genet A</source>
                <volume>146A</volume>
                <fpage>512</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">18203164</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.cathey.2009.38">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cathey</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eaves</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simensen</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kudo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevenson</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friez</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands.</article-title>
                <source>J Med Genet</source>
                <volume>47</volume>
                <fpage>38</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">19617216</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.encarna__o.2009.76">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Encarna&#x000e7;&#x000e3;o</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacerda</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costa</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prata</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coutinho</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopes</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pineda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ignatius</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galvez</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mustonen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vieira</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lima</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alves</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Molecular analysis of the GNPTAB and GNPTG genes in 13 patients with mucolipidosis type II or type III - identification of eight novel mutations.</article-title>
                <source>Clin Genet</source>
                <volume>76</volume>
                <fpage>76</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">19659762</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.falikzaccai.2003.211">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Falik-Zaccai</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeigler</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bargal</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bach</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borochowitz</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raas-Rothschild</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Mucolipidosis III type C: first-trimester biochemical and molecular prenatal diagnosis.</article-title>
                <source>Prenat Diagn</source>
                <volume>23</volume>
                <fpage>211</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">12627421</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.gao.2011.107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luo</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>QK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>JY</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Identification of compound heterozygous mutations in GNPTG in three siblings of a Chinese family with mucolipidosis type III gamma.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>102</volume>
                <fpage>107</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20951619</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.kang.2010.677">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kang</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riazuddin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mundorff</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krasnewich</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mullikin</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drayna</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Mutations in the lysosomal enzyme-targeting pathway and persistent stuttering.</article-title>
                <source>N Engl J Med.</source>
                <volume>362</volume>
                <fpage>677</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">20147709</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.kornfeld.2014">
              <mixed-citation publication-type="webpage">Kornfeld S, Sly WS. I-Cell disease and pseudo-Hurler polydystrophy: disorders of lysosomal enzyme phosphorylation and localization. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> New York, NY: McGraw-Hill. Chap 138. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/content.aspx?bookid=971&#x00026;sectionid=63720561">online</ext-link>. 2014. Accessed 12-21-15.</mixed-citation>
            </ref>
            <ref id="ml3c.REF.kudo.2006.451">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kudo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brem</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canfield</surname>
                    <given-names>WM</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Mucolipidosis II (I-cell disease) and Mucolipidosis III (classical pseudo-Hurler polydystrophy) are caused by mutations in the GlcNAc-phosphotransferase alpha / beta-subunits precursor gene.</article-title>
                <source>Am J Hum Genet</source>
                <volume>78</volume>
                <fpage>451</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">16465621</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.leroy.2007">
              <mixed-citation publication-type="book">Leroy JG. Oligosaccharidoses, disorders allied to the oligosaccharides. In: Rimoin DL, Connor JM, Pyeritz RE, Korf BR, eds. <italic toggle="yes">Emery and Rimoin&#x02019;s Principles and Practice of Medical Genetics.</italic> 5 ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2007:2413-48.</mixed-citation>
            </ref>
            <ref id="ml3c.REF13">
              <mixed-citation publication-type="confproc">MPS Society. First International Consensus Meeting on Bisphosphonates Therapy in Oligosaccharidoses. Christchurch, New Zealand. 2008.</mixed-citation>
            </ref>
            <ref id="ml3c.REF.otomo.2009.145">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Otomo</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muramatsu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yorifuji</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okuyama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakabayashi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukao</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okamoto</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inui</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozono</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakai</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Mucolipidosis II and III alpha/beta: mutation analysis of 40 Japanese patients showed genotype-phenotype correlation.</article-title>
                <source>J Hum Genet</source>
                <volume>54</volume>
                <fpage>145</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">19197337</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.persichetti.2009.978">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Persichetti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chuzhanova</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dardis</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tappino</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pohl</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>NS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosano</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balducci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paciotti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dominissini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montalvo</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sibilio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rigoldi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Rocco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parenti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orlacchio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bembi</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>DN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filocamo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beccari</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Identification and molecular characterization of six novel mutations in the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTG) gene in patients with mucolipidosis III gamma.</article-title>
                <source>Hum Mutat</source>
                <volume>30</volume>
                <fpage>978</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">19370764</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.pohl.2009.221">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pohl</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiede</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castrichini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cantz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gieselmann</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braulke</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Compensatory expression of human N-acetylglucosaminyl-1-phosphotransferase subunits in mucolipidosis type III gamma.</article-title>
                <source>Biochim Biophys Acta</source>
                <volume>1792</volume>
                <fpage>221</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19708128</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.pohl.2010.124">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pohl</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Encarnac&#x000e3;o</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castrichini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller-Loennies</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muschol</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braulke</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Loss of N-acetylglucosamine-1-phosphotransferase gamma subunit due to intronic mutation in GNPTG causes mucolipidosis type III gamma: Implications for molecular and cellular diagnostics.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>152A</volume>
                <fpage>124</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">20034096</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.raasrothschild.2004.e52">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Raas-Rothschild</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bargal</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldman</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben-Asher</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groener</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toutain</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stemmer</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben-Neriah</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flusser</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beemer</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penttinen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olender</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rein</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bach</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeigler</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Genomic organisation of the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) and its mutations in mucolipidosis III.</article-title>
                <source>J Med Genet</source>
                <volume>41</volume>
                <fpage>e52</fpage>
                <pub-id pub-id-type="pmid">15060128</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.raasrothschild.2000.673">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Raas-Rothschild</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cormier-Daire</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bao</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Genin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brewer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeigler</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toth</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roe</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canfield</surname>
                    <given-names>WM</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Molecular basis of variant pseudo-hurler polydystrophy (mucolipidosis IIIC).</article-title>
                <source>J Clin Invest</source>
                <volume>105</volume>
                <fpage>673</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">10712439</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.robinson.2002.681">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baker</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noble</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>David</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sillence</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hofman</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cundy</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>25</volume>
                <fpage>681</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">12705498</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.schrader.2011.12">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schrader</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heravi-Moussavi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Senz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whelan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ha</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eydoux</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nielsen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallagher</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oloumi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boyd</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirst</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shah</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marra</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huntsman</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Using next-generation sequencing for the diagnosis of rare disorders: a family with retinitis pigmentosa and skeletal abnormalities.</article-title>
                <source>J Pathol.</source>
                <volume>225</volume>
                <fpage>12</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21792934</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.smuts.2009.77">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smuts</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Potgieter</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Westhuizen</surname>
                    <given-names>FH</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Combined tarsal and carpal tunnel syndrome in mucolipidosis type III. A case study and review.</article-title>
                <source>Ann NY Acad Sci</source>
                <volume>1151</volume>
                <fpage>77</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">19154518</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.spranger.1970.113">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spranger</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiedemann</surname>
                    <given-names>HR</given-names>
                  </name>
                </person-group>
                <year>1970</year>
                <article-title>The genetic mucolipidoses. Diagnosis and differential diagnosis.</article-title>
                <source>Humangenetik</source>
                <volume>9</volume>
                <fpage>113</fpage>
                <lpage>39</lpage>
                <pub-id pub-id-type="pmid">4246487</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.steet.2005.369">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Steet</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hullin</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kudo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinelli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bosshard</surname>
                    <given-names>NU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaffner</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kornfeld</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinmann</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A splicing mutation in the alpha/beta GlcNAc-1-phosphotransferase gene results in an adult onset form of mucolipidosis III associated with sensory neuropathy and cardiomyopathy.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>132</volume>
                <fpage>369</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">15633164</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.tappino.2009.e956">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tappino</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chuzhanova</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Regis</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dardis</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corsolini</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stroppiano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tonoli</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beccari</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosano</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mucha</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szlago</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Rocco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>DN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filocamo</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Molecular characterization of 22 novel UDP-N-acetylglucosamine-1-phosphate transferase alpha- and beta-subunit (GNPTAB) gene mutations causing mucolipidosis types II alpha/beta and III alpha/beta in 46 patients.</article-title>
                <source>Hum Mutat.</source>
                <volume>30</volume>
                <fpage>E956</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">19634183</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.tiede.2004.535">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tiede</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cantz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raas-Rothschild</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muschol</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000fc;rger</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ullrich</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braulke</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>A novel mutation in UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) in two siblings with mucolipidosis type III alters a used glycosylation site.</article-title>
                <source>Hum Mutat</source>
                <volume>24</volume>
                <fpage>535</fpage>
                <pub-id pub-id-type="pmid">15532026</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.tiede.2005.1109">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tiede</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Storch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000fc;bke</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henrissat</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bargal</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raas-Rothschild</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braulke</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Mucolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase.</article-title>
                <source>Nat Med</source>
                <volume>11</volume>
                <fpage>1109</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">16200072</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.traboulsi.1986.592">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Traboulsi</surname>
                    <given-names>EI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maumenee</surname>
                    <given-names>IH</given-names>
                  </name>
                </person-group>
                <year>1986</year>
                <article-title>Ophthalmologic findings in mucolipidosis III (pseudo-Hurler polydystrophy).</article-title>
                <source>Am J Ophthalmol.</source>
                <volume>102</volume>
                <fpage>592</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">3777077</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.tylkiszyma_ska.2002.214">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tylki-Szyma&#x00144;ska</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Czartoryska</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groener</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>&#x00141;ugowska</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Clinical variability in mucolipidosis III (pseudo-Hurler polydystrophy).</article-title>
                <source>Am J Med Genet.</source>
                <volume>108</volume>
                <fpage>214</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11891688</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.umehara.1997.167">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Umehara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsumoto</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuriyama</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sukegawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osame</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Mucolipidosis III (pseudo-Hurler polydystrophy); clinical studies in aged patients in one family.</article-title>
                <source>J Neurol Sci</source>
                <volume>146</volume>
                <fpage>167</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">9077513</pub-id>
              </element-citation>
            </ref>
            <ref id="ml3c.REF.zolkipli.2005.772">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zolkipli</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noimark</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cleary</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Owens</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vellodi</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Temporomandibular joint destruction in mucolipidosis type III necessitating gastrostomy insertion.</article-title>
                <source>Eur J Pediatr</source>
                <volume>164</volume>
                <fpage>772</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">16041526</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="ml3c.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="ml3c.Suggested_Reading.reflist0">
            <ref id="ml3c.REF.kornfeld.1986.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kornfeld</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>1986</year>
                <article-title>Trafficking of lysosomal enzymes in normal and disease states.</article-title>
                <source>J Clin Invest</source>
                <volume>77</volume>
                <fpage>1</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">3003148</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="ml3c.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="ml3c.Acknowledgments">
          <title>Acknowledgments</title>
          <p>We thank the &#x0201c;Vaincre les Maladies Lysosomales&#x0201d; association for their continuous support and for the research grants for our research projects on ML III gamma and ML II.</p>
          <p>We thank Dr. Marsha Zeigler (PhD) and her team for what she taught us, and for her help in the diagnosis of patients.</p>
          <p>We thank Mrs. Ruth Bargal (MSc) for her continuous support and cooperation.</p>
          <p>We thank the families for their cooperation.</p>
        </sec>
        <sec id="ml3c.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>5 July 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>29 September 2011 (cd) Revision: sequence analysis, UPD, and prenatal testing available clinically</p>
            </list-item>
            <list-item>
              <p>28 January 2010 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>28 August 2009 (arr) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
